According to the latest market research study by Technavio, the global multiple myeloma drugs market is expected to grow at a CAGR of close to 9% during the forecast period 2017 to 2021.
This report by Technavio provides an in-depth analysis of the global multiple myeloma drugs market in terms of revenue and emerging market trends. The report also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.
Technavio research analysts categorize the market based on the therapy
Source: Technavio
Click here to request a free sample of this report
The top three revenue contributing therapy segments are discussed below
Biologic therapy: Biological therapy drugs use the body’s immune system to fight myeloma cells. The segment is expected to benefit from the increasing preference of physicians to adopt biologics owing to their established clinical profile.
“Biologic therapies are primarily characterized by monoclonal antibodies and immune-modulating agents. The approval of monoclonal antibodies such as DARZALEX and EMPLICITI is expected to drive growth in this segment,” says Srinivas Sashidhar, a lead analyst at Technavio for research on oncology.
Targeted therapy: Targeted therapy focuses on specific abnormalities within cancer cells that enable to survive. Targeted therapies are mostly classified into proteasome inhibitors and histone deacetylase inhibitors. Histone deacetylase inhibitors include FARYDAK (panobinostat), which block the action of a substance in myeloma cells that disrupts proteins and helps in killing the myeloma cells.
Chemotherapy: Chemotherapy drugs act by destroying fast-growing cells, including myeloma cells. These drugs can be given through intravenous or oral form. High doses of chemotherapy drugs are also given before a stem cell transplant. Some of the chemotherapy drugs include vincristine, etoposide, melphalan, cyclophosphamide, liposomal doxorubicin, doxorubicin, and bendamustine.
Ask an analyst to know more about this report
The top vendors operating in the global multiple myeloma drugs market are:
- Amgen
- Celgene
- Johnson & Johnson
- Novartis
- Takeda Pharmaceuticals
The other prominent vendors in the market include AB Science, AbbVie, Acceleron Pharma, Acetylon Pharmaceuticals, Adaptimmune Therapeutics, Alexion Pharmaceuticals, AmpliMed Corporation, Array BioPharma, Benovus Bio, BioInvent, Biokine Therapeutics, Biotest, bluebird bio, Bristol-Meyer Squibb, Calithera Biosciences, CASI Pharmaceuticals, Celldex Therapeutics, Cellectar Biosciences, Chroma Therapeutics, Cleave Biosciences, Curis, Dicerna Pharmaceuticals, Eureka Therapeutics, F. Hoffmann-La Roche, Geron Corporation, GlycoMimetics, GlaxoSmithKline, ImmunoGen, Immunomedics, Innate Pharma, JW Pharmaceutical, Karyopharm Therapeutics, Kyowa Hakko Kirin, Merck, Midatech Pharma, Mirna Therapeutics, Molecular Partners, MorphoSys, NOXXON Pharma, Oncoceutics, Oncolytics Biotech, OncoPep, Oncopeptides, Ono Pharmaceutical, Otsuka Pharmaceuticals, Patrys, PharmaMar, Polyphor, Prothena Therapeutics, Sanofi, Sevion Therapeutics, Specialised Therapeutics, Spectrum Pharmaceutical, SymBio Pharmaceuticals, TaiGen Biotechnology, Tragara Pharmaceuticals, Vaxil Therapeutics, and Vivolux.
A more detailed analysis is available in the Technavio report titled, ‘Global Multiple Myeloma Drugs Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports
- Global Next-Generation Biologics Market 2016-2020
- Global Lung Cancer Therapeutics Market 2016-2020
- Global Cancer Monoclonal Antibodies Market 2017-2021
To read more press releases – click here
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
https://www.technavio.com/
